A few months ago, the father of marijuana research, Professor Raphael Mechoulam, unveiled his newest discovery: the cannabidiolic acid (EPM 301). His introduction of the latest, patented substance caused much excitement in the marijuana industry, especially within the medical cannabis sector. His compound is entirely stable, synthetic, and an acid-based cannabinoid molecule. It was announced to the world in collaboration with EPM, a global biotechnology company in America. EPM seeks to bridge the gap between the pharmaceutical industry and the cannabis market.